Cited by 447Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChronic Myeloid Leukemia Treatments

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Open access

McMahon, Christine M., Ferng, Timothy, Canaani, Jonathan, Wang, Eunice S., Morrissette, Jennifer J.D., Eastburn, Dennis J., Pellegrino, Maurizio, Durruthy-Durruthy, Robert, Watt, Christopher D., Asthana, Saurabh, Lasater, Elisabeth A., DeFilippis, RosaAnna, Peretz, Cheryl A.C., McGary, Lisa H.F., Deihimi, Safoora, Logan, Aaron C., Luger, Selina M., Shah, Neil P., Carroll, Martin, Smith, Catherine C., Perl, Alexander E.·2019·Cancer Discovery

DOI 10.1158/2159-8290.cd-18-1453PMC PMC11994087

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clinical trials of gilteritinib. Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS. Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR–ABL1 fusions were identified at progression. Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously. These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML. Significance: Comprehensive serial genotyping of AML specimens from patients treated with the selective FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal selection and evolution mediate clinical resistance to tyrosine kinase inhibition in FLT3-mutated AML. Our data support the development of combinatorial targeted therapeutic approaches for advanced AML. See related commentary by Wei and Roberts, p. 998. This article is highlighted in the In This Issue feature, p. 983

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1453

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,152
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 873
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S. N., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 738
Self-citation

Show all 35 references

Research works printed but not linked: 1

Cortes, 2018, Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated relapsed/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial [abstract]

Sorted by citations

Items 301–400 of 447

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia
Wei, Y. U. A. N., Zhang, S., & Zhu, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0090 · Cited by 3
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis
Yang, J., & Friedman, R. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101894 · Cited by 3
FLT3 -mutated AML: immune evasion through exosome-mediated mechanisms and innovative combination therapies targeting immune escape
Saadh, M. J., Abdulsahib, W. K., Ashurova, D., Sanghvi, G. V., Ballal, S., Sharma, R., Pathak, P. K., Aman, S., Kumar, A., Sead, F. F., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2461632 · Cited by 3
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
Perl, A. E. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101257 · Cited by 3
Self-citation
Single-Cell Sequencing: Ariadne’s Thread in the Maze of Acute Myeloid Leukemia
Redavid, I., Conserva, M. R., Anelli, L., Zagaria, A., Specchia, G., Musto, P., & Albano, F. (2022) · Diagnostics · doi:10.3390/diagnostics12040996 · Cited by 3
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
Bruno, S., Bochicchio, M. T., Franchini, E., Padella, A., Marconi, G., di Rorà, A. G. L., Venturi, C., Raffini, M., Prisinzano, G., Ferrari, A., et al. (2019) · Journal of Oncology · doi:10.1155/2019/5985923 · Cited by 3
Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor
Thakral, B., Daver, N. G., Tang, Z., Patel, K. P., Ok, C. Y., Loghavi, S., Khoury, J. D., Alotaibi, A. S., Konopleva, M. Y., Yilmaz, M. E., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1797008 · Cited by 3
Targeting Hyperactive Ras Signaling in Pediatric CancerPreprint
Levinson, A. L., Shannon, K., & Huang, B. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041572 · Cited by 3
Genotype-immunophenotype relationships in NPM1 -mutant AML clonal evolution uncovered by single cell multiomic analysisPreprint
Drucker, M., Lee, D., Zhang, X., Kain, B. N., Bowman, M., Nicolet, D., Wang, Z., Stone, R. M., Mrózek, K., Carroll, A. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.623033 · Cited by 3
In Vivo Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in NRAS -Mutant CancerPreprint
Decker, M., Huang, B. J., Ware, T. B., Boone, C. D., Tang, M., Ybarra, J., Sale, M. J., Francois, R. A., Ballapuram, A. C., Taran, K. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.20.644389 · Cited by 3
Self-citation
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaPreprint
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.10.658786 · Cited by 3
Self-citation
Leukemia mutated proteins PHF6 and PHIP form a chromatin complex that represses acute myeloid leukemia stemness
Pawar, A. S., Somers, P., Alex, A., Grana, J., Feist, V. K., George, S. S., Jalnapurkar, S. S., Antony, C., Verner, R., White-Brown, S. K., et al. (2025) · Genes & Development · doi:10.1101/gad.352602.125 · Cited by 3
Self-citation
Bayesian inference of fitness landscapes via tree-structured branching processes
Luo, X. G., Kuipers, J., Rupp, K., Takahashi, K., & Beerenwinkel, N. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf193 · Cited by 5
Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
Fu, L., & Luo, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_8 · Cited by 2
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia
Eriksson, J., Zheng, S., Popa, M. L., Bao, J., Dai, J., Wang, W., McCormack, E., Vähärautio, A., & Tang, J. P. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3753 · Cited by 2
Genotype-immunophenotype relationships in NPM1 -mutated AML clonal evolution uncovered by single-cell multiomic analysis
Drucker, M., Lee, D., Bowman, M. B., Zhang, X., Kain, B. N., Nicolet, D., Bandopadhyay, R., Singh, V., Wang, Z., Stone, R. M., et al. (2026) · Blood · doi:10.1182/blood.2025030772 · Cited by 2
Traipsing Through Muddy Waters
Kuykendall, A. T., Tokumori, F. C., & Komrokji, R. S. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.005 · Cited by 2
Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition
Perl, A. E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00499 · Cited by 2
Self-citation
Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling
Batzilla, A., Lu, J., Kivioja, J. L., Putzker, K., Lewis, J., Zenz, T., & Huber, W. K. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010438 · Cited by 2
Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications
He, X., Xia, M.-F., Teng, J.-Y., Zhou, B. S., & Wang, Q. (2023) · Genome Instability & Disease · doi:10.1007/s42764-023-00104-6 · Cited by 3
Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia in vitro
Xu, Y., Baylink, D. J., Chen, C.-S., Tan, L. D., Xiao, J., Park, B. K., Valladares, I., Reeves, M. E., & Cao, H. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1286863 · Cited by 2
Application of Microfluidics in Drug Development
Parhizkar, M., Wang, F., Tsitouridou, A., & Tsaoulidis, D. A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-60717-2_12 · Cited by 2
Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia
Lints, R., Walker, C. A., Delfi, O., Prouse, M., de Silva, M. P., Bohlander, S. K., & Wood, A. (2024) · Biology Open · doi:10.1242/bio.060523 · Cited by 2
Precision Medicine for Older AML Patients
Testa, U., Castelli, G., & Pelosi, E. (2025) · Onco · doi:10.3390/onco5030042 · Cited by 2
Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML
Sussman, R. T., Manning, B. S., Ackerman, D., Bigdeli, A., Pammer, P., Velu, P., Luger, S. M., Bagg, A., Carroll, M. P., & Morrissette, J. J. D. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.04.004 · Cited by 2
Self-citation
Aktuelle Therapieoptionen bei rezidivierter/refraktärer AML
Modemann, F., Ghandili, S., Oelrich, J., Bokemeyer, C., & Fiedler, W. (2022) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-022-9706-y · Cited by 2
Sidestepping SHP2 inhibition
Popescu, B. O., & Shannon, K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230082 · Cited by 2
C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemiaPreprint
Sabatier, M., Birsen, R., Lauture, L., Dehairs, J., Angelino, P., Mouche, S., Heiblig, M., Boët, E., Sahal, A., Saland, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.15.488522 · Cited by 2
PTPN11 Mutation Clonal Hierarchy in Acute Myeloid LeukemiaPreprint
Fobare, S., Sharpe, C., Quinn, K. R., Bryant, K., Miles, L. A., Bowman, R. L., Cheney, C. M., Furby, C., Long, M., Fyock, K., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.612239 · Cited by 2
Self-citation
Ferroptose, métabolisme lipidique, C/EBPα et résistance thérapeutique dans les leucémies aiguës myéloïdes
Birsen, R., Lauture, L., Sarry, J., & Tamburini, J. (2023) · médecine/sciences · doi:10.1051/medsci/2023171 · Cited by 1
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients
He, G., Belmont, E., Karrison, T. G., Stock, W., LaBelle, J. L., Kosuri, S., Larson, R. A., Kline, J. P., Riedell, P. A., Nawas, M. T., et al. (2024) · Annals of Translational Medicine · doi:10.21037/atm-23-1941 · Cited by 1
Star wars against leukemia: attacking the clones
Toma, M. M., & Skórski, T. (2024) · Leukemia · doi:10.1038/s41375-024-02369-6 · Cited by 3
A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02
Arai, H., Hosono, N., Chi, S., Fukushima, K., Ikeda, D., Iyama, S., Gotoh, A., Ikezoe, T., Yoshida, C., Yoshimoto, G., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03895-w · Cited by 1
Leukemogenic Kras mutation reprograms multipotent progenitors to facilitate its spread through the hematopoietic system
Jang, G., Park, R., Esteva, E., Hsu, P.-F., Feng, J., Upadhaya, S., Sawai, C. M., Aifantis, I., Fooksman, D., & Reizis, B. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20240587 · Cited by 2
A PI3K Inhibitor with Low Cardiotoxicity and Its Synergistic Inhibitory Effect with Gilteritinib in Acute Myelogenous Leukemia (AML) Cells
Wu, T., Chen, Y., Gong, Y., Lu, M., Yang, C., Yang, Y., Ling, Y., & Zhou, Y. (2025) · Molecules · doi:10.3390/molecules30112347 · Cited by 1
Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias
Alekrish, Y., Alotaibi, S., Iqbal, Z., & Aleem, A. (2025) · Cureus · doi:10.7759/cureus.86322 · Cited by 1
Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review
Swanson, L., Sharp, J., Liaw, A., Abdallah, D. S. A., & Duriancik, D. M. (2025) · Cureus · doi:10.7759/cureus.95338 · Cited by 1
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?
Nicol, W., & Wei, A. H. (2025) · Hematology · doi:10.1182/hematology.2025000756 · Cited by 1
ATGL suppresses ferroptosis in acute myeloid leukemia cells by modulating the CEBPα/SCD1 axis and induces gilteritinib resistance
Yuan, S., Zhou, Y., Xiao, W., Liu, N., Zhang, P., Zhang, Y., Deng, J., Fang, L., Zhang, X., & Lou, S. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08388-0 · Cited by 1
Lactate metabolism and epigenetic reprogramming drive c-KIT hyperactivation to mediate Gilteritinib resistance: Rationale for c-KIT degraders over kinase inhibitors
Zhao, Y., Wang, Y., Liu, N., Yang, Y., Li, J., Huang, Z., Lan, M., Yang, S., Liu, S., Zhou, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.045 · Cited by 1
Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models
Fu, Y.-H., Ng, K. M., Tseng, C.-Y., Huang, A.-C., Tu, C.-H., Chen, W.-C., Lang, P.-C., Hsiung-Fei, C., & Lin, L. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02957-8 · Cited by 2
Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemia
Fobare, S., Sharpe, C., Quinn, K. R., Bryant, K., Miles, L. A., Bowman, R. L., Cheney, C. M., Furby, C., Long, M., Fyock, K., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.193779 · Cited by 1
Self-citation
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game
Noorafrooz, M., Noorafrooz, R., Barosi, G., & Gale, R. P. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101385 · Cited by 1
Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold?
Schreiber, J., Hopfinger, G., & Gleixner, K. V. (2026) · Cancers · doi:10.3390/cancers18061034 · Cited by 1
Targeting oncogenic FLT3 uncovers a ferroptosis vulnerability through selenocysteine recoding in acute myeloid leukaemia
Li, M., Zhu, Y., Kageyama, Y., Furudate, K., Kitano, A., Tan, T., Feng, M., Zhou, J., Wang, T., Taylor, R. J., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-02016-5 · Cited by 1
FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies
Silvestrini, G., Travaglini, S., Guarnera, L., Lelli, N., Divona, M., Casciani, E., Ceccolini, S., Falconi, G., Ottone, T., & Voso, M. T. (2026) · Cancers · doi:10.3390/cancers18162586 · Cited by 1
Is there evidence for the use of FLT3 inhibitors as maintenance therapy in AML?
Levis, M. J. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101246 · Cited by 1
Filled with Desire, Perceive Molecules
Strand, R., & Engen, C. (2022) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-92612-0_15 · Cited by 1
Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
Katagiri, S., Furuya, N., Akahane, D., Chi, S., Minami, Y., Harada, Y., Harada, H., & Gotoh, A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s417137 · Cited by 1
Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia
Fobare, S., Elgamal, O. A., Wunderlich, M., Stahl, E. H., Mehmood, A., Furby, C., Lerma, J. R., Sesterhenn, T. M., Pan, J., Rai, J., et al. (2024) · Cancers · doi:10.3390/cancers16030569 · Cited by 1
Single nucleus DNA sequencing of flow sorted archived frozen and formalin fixed paraffin embedded solid tumors
Zhou, Y., Chen, X., Chapman, J. S., & Barrett, M. T. (2024) · BMC Genomics · doi:10.1186/s12864-024-10850-w · Cited by 1
Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06
Cavallaro, G., Salmoiraghi, S., Cavagna, R., Pavoni, C., Belotti, C., Milani, M., Oldani, E., Frigeni, M., Intermesoli, T., Grassi, A., et al. (2025) · Leukemia Research · doi:10.1016/j.leukres.2025.107702 · Cited by 1
Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia
Herrera, D. A., Bruno, X. J., Devitt, K., Conant, J. L., & Gardner, J.-A. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106494 · Cited by 1
Future Developments: Novel Agents
Chua, C. C., & Wei, A. H. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_17 · Cited by 1
Molecular Features Associated with Response to Enasidenib Plus Azacitidine in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia
Risueño, A., See, W. L., Prébet, T., Dinardo, C. D., Döhner, H., Stein, E. M., Fathi, A. T., Vyas, P., Quek, L. S., Gandhi, A. K., et al. (2023) · Journal of Clinical Haematology · doi:10.33696/haematology.4.054 · Cited by 1
Converging molecular evolution in acute myeloid leukaemiaPreprint
Engen, C., Hellesøy, M., Dowling, T. H., Eldfors, S., Ferrell, B., Gullaksen, S., Popa, M. L., Brendehaug, A., Karjalainen, R., Mejlænder-Andersen, E., et al. (2020) · medRxiv · doi:10.1101/2020.11.03.20222885 · Cited by 1
BETing on rational combination therapy in mutant FLT3 acute myeloid leukemia
Stone, R. M. (2020) · Haematologica · doi:10.3324/haematol.2020.274753 · Cited by 1
[Effect of calmodulin on myometrial cell membrane Ca2+,Mg2+-ATPase activity].
Kravtsov, O. V., & Kravtsova, V. V. (2000) · PubMed · Cited by 1
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands through suppression of ERK in AML and combined inhibition of CXCR4/E-selectin enhances anti-leukemia efficacy of FLT3-targeted therapyPreprint
Jia, Y., Zhang, W., Basyal, M., Chang, K. H., Ostermann, L. B., Burks, J. K., Ly, C., Mu-Mosley, H., Zhang, Q., Han, X., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2277452/v1 · Cited by 1
Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AMLPreprint
Popescu, B. O., Stahlhut, C. E., Tarver, T. C., Wishner, S., Lee, B. J., Peretz, C. A. C., Luck, C., Phojanakong, P. J., Cámara, J. A., Hongo, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.01.518665 · Cited by 1
Self-citation
Evaluation of hypereosinophilia in a case ofFLT3-mutant acute myeloid leukemia treated with gilteritinibPreprint
Martinez-Gutierrez, L. N., Burgher, B., Glynias, M. J., Alvarado, D., Griffiths, E. A., Glenn, S. T., & Sung, P. J. (2023) · Molecular Case Studies · doi:10.1101/mcs.a006279 · Cited by 1
Next Generation Sequencing Study of clonal Evolution in AML Shows Mutations in RAS-MAPK Signaling Pathway as an Emergent Mechanism of Progression in Low-Intensity TreatmentsPreprint
Jiménez‐Vicente, C., López‐Guerra, M., Pérez‐Valencia, A. I., Munárriz, D., Guijarro, F., Castaño‐Díez, S., Martínez‐Roca, A., Cortés‐Bullich, A., Cardús, A., Esteban, D., et al. (2024) · Preprints.org · doi:10.20944/preprints202401.0604.v1 · Cited by 1
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemiaPreprint
Chow, R. D.-W., Velu, P., Deihimi, S., Belman, J., Youn, A., Shah, N., Luger, S. M., Carroll, M. P., Morrissette, J. D., & Bowman, R. L. (2024) · medRxiv · doi:10.1101/2024.08.31.24312756 · Cited by 1
Self-citation
Acute myeloid leukaemia
Beinortas, T., Gallipoli, P., & Huntly, B. J. P. (2025) · doi:10.1002/9781119706687.ch32 · Cited by 1
Molecular Pathways and Potential for Targeted Therapies in the Treatment of Early T-cell Precursor Acute Lymphoblastic Leukemia
Donnelly, L. L., Gardner, J.-A., Conant, J. L., & Devitt, K. (2020) · Advances in Molecular Pathology · doi:10.1016/j.yamp.2020.07.003
Mechanisms of Resistence of New Target Drugs in Acute Myeloid Leukemia
Capelli, D., Saraceni, F., Menotti, D., Fiorentini, A., & Olivieri, A. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94978
Unraveling a T-ALL Tapestri
Ng, A. P. (2021) · Blood · doi:10.1182/blood.2020008467
Treatment of Relapsed and Refractory AML: Non-intensive Approach in Unfit Patients
Récher, C. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-72676-8_12
AML-149: Efficacy and Safety of Azacytidine in Combination with Fludarabine and High-Dose Cytarabine with G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Open-Label, Phase II Study
Aoun, S. M. A., Motabi, I., Al‐Ammari, M., lshehry, N. A., Marei, M. A., Albtoosh, B., Tailor, I. K., Altaf, S. Y., Zaidi, S., & Alfayez, M. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01682-7
Bypass, Escape, or Mutate: The Resistant Clones in Midostaurin-treated FLT3-ITD AML
Sheehy, J. J., & Lane, S. (2021) · The Hematologist · doi:10.1182/hem.v18.5.202153
Bacon-Wrapped Chemo: Can Liposomal Cytarabine/Daunomycin Improve Outcomes for Children With Newly Diagnosed AML Versus Conventional Therapy?
Lamble, A. J., & Tasian, S. K. (2021) · The Hematologist · doi:10.1182/hem.v18.5.2021510
Three essays on licensing university inventions
Munteanu, R. (2007) · eScholarship (California Digital Library)
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Motabi, I., Aoun, S. M. A., Al‐Ammari, M., Albtoosh, B. M., Iqbal, S., Altaf, S. Y., Tailor, I. K., Alnoamani, M. S., AlGhamdi, M. S., Zaidi, S. Z. A., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.019
Faculty Opinions recommendation of Cutting edge molecular therapy for acute myeloid leukemia.
Liu, M. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738375855.793584684
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
Lou, D., Liu, L., & Qin, W. (2022) · Diseases & Research · doi:10.54457/dr.202201002
Leukemias, Lymphomas, and Plasma Cell Disorders
Morrissette, J. J. D., Roth, J. J., Luger, S. M., & Stadtmauer, E. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-812534-2.00012-6
Self-citation
Emergence of a BCR::ABL1 rearrangement following a uniquely complex clonal evolution pattern in a patient undergoing Fms‐like tyrosine kinase 3 inhibitor therapy for acute myeloid leukemia
Park, B., Kim, J., Kim, M., Cho, Y., Hwang, S., Jang, S., Seo, E., Choi, E., & Park, C. (2022) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13973
Cellular distribution of IDH mutations in AML during morphologic remission
Ramanan, R., Tiong, I. S., Ivey, A., Ong, D. M., Brown, F. C., Chua, C. C., Das, T., & Curtis, D. J. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106993
Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN
van den Heuvel, R. (2023) · doi:10.55788/fad0d3d1
Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Smith, C. C., Viny, A. D., Massi, E., Kandoth, C., Socci, N. D., Rapaport, F., Najm, M., Medina-Martinez, J. S., Papaemmanuil, E., Tarver, T. C., et al. (2023) · doi:10.1158/1078-0432.c.6530567
Self-citation
Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Smith, C. C., Viny, A. D., Massi, E., Kandoth, C., Socci, N. D., Rapaport, F., Najm, M., Medina-Martinez, J. S., Papaemmanuil, E., Tarver, T. C., et al. (2023) · doi:10.1158/1078-0432.c.6530567.v1
Self-citation
Therapie der rezidivierten/refraktären akuten myeloischen Leukämie
Modemann, F., Ghandili, S., Bokemeyer, C., & Fiedler, W. (2023) · Im Focus Onkologie · doi:10.1007/s15015-023-3076-7
A critical role for PLCG1 in RAS activation by BCR-ABL1 and FLT3-ITDPreprint
Szeto, M. Y., Mase, A., Kulhanek, K. R., Banerjee, S., Rubio, I., Roose, J. P., & Shah, N. P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.07.536070
Self-citation
Strategies to overcome drug resistance in FLT3+ AML
Yang, J. (2023) · doi:10.15626/lud.509.2023
FLT3-ITD-Specific PROTAC: : Enhanced Safety and Increased Synergy with Venetoclax in Acute Myeloid LeukemiaPreprint
Tan, Y., Xin, L., Wang, Q., Xu, R., Tong, X., Chen, G., Ma, L., Yang, F., Jiang, H., Zhang, N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3699368/v1
Chromosomal and Genomic Alterations in Pediatric AML
Lamble, A. J., & Huang, B. J. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_2
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Zheng, S., Tong, Y., Yang, L., Chen, J., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06050-x · Cited by 1
RASopathy Genes: Germline Risk and Somatic Cancers
Ney, G. M., Kratz, C. P., & Stewart, D. R. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_22
Protein disulfide isomerase family is a potential therapeutic target in acute myeloid leukemiaPreprint
Lin, L., Lu, Y., Zhang, Y., Qi, N., Huang, S., Peng, M., Zhao, Z., Yang, A., Niu, Z.-Y., Wang, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-5764412/v1
Bayesian inference of fitness landscapes via tree-structured branching processesPreprint
Luo, X. G., Kuipers, J., Rupp, K., Takahashi, K., & Beerenwinkel, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.634649
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies
Duployez, N., & Preudhomme, C. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.06.001 · Cited by 3
Developmental stage modulates the prognostic impact of RAS pathway mutations in AML patients undergoing Allo-HSCT
Yuan, X., Wu, Y., Wang, Y., Wu, J., Zhu, P., Yang, L., Lai, X., Liu, L., Shi, J., Yu, J., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06694-3
Strengths and limitations of Ba/F3 cells in modelling FLT3-driven AML resistance
Yang, J., & Friedman, R. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130456
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingPreprint
Huang, B. J., D’Souza, J., Batingana, A. R., Harris, M., Wang, X., Hwang, E., Wandler, A. M., Burgess, M. R., Li, Q., Meshinchi, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.688312
Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia
Pang, H., Wan, C., Zhang, M., Ge, S., Huang, Y.-H., Qiu, C., Xue, S., Wu, D., & Liu, S. (2025) · Journal of Visualized Experiments · doi:10.3791/69655
Additional file 6 of A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311691
Additional file 15 of A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311664
Additional file 7 of A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib
Li, K.-X., Wu, H.-Y., Pan, W.-Y., Guo, M.-Q., Qiu, D.-Z., He, Y., Li, Y.-H., Yang, D.-H., & Huang, Y.-X. (2022) · Figshare · doi:10.6084/m9.figshare.19311694
Additional file 2 of Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
Hu, C., Zhang, Y., Yang, J., Xu, Y., 邓婷芬, Li, Y., Xu, S., Wang, S., & Wang, P. (2024) · Figshare · doi:10.6084/m9.figshare.26211615
Additional file 1 of A precision medicine classification for treatment of acute myeloid leukemia in older patients
Mims, A. S., Kohlschmidt, J., Borate, U., Blachly, J. S., Orwick, S. J., Eisfeld, A.-K., Papaioannou, D., Nicolet, D., Mrózek, K., Stein, E., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14833368
Self-citation

Authors: McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., Lasater, E. A., DeFilippis, R., Peretz, C. A. C., McGary, L. H. F., Deihimi, S., Logan, A. C., Luger, S. M., Shah, N. P., Carroll, M., Smith, C. C., & Perl, A. E.
Affiliations: University of Pennsylvania (US)
University of California, San Francisco (US)
Tel Aviv University (IL)
Roswell Park Comprehensive Cancer Center (US)
Mission Bio (United States) (US)
United States Department of Veterans Affairs (US)
ORCID: McMahon, Christine M.
Ferng, Timothy
Canaani, Jonathan
Wang, Eunice S.
Morrissette, Jennifer J.D.
Eastburn, Dennis J.
Pellegrino, Maurizio
DeFilippis, RosaAnna
Peretz, Cheryl A.C.
McGary, Lisa H.F.
Logan, Aaron C.
Luger, Selina M.
Shah, Neil P.
Carroll, Martin
Smith, Catherine C.
Perl, Alexander E.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2019-08-01
Volume: 9
Issue: 8
Pages: 1050-1063
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-18-1453
PMC: PMC11994087
OpenAlex: W2946259536
Cited by: 446
References: 35
Citations by year: 2026: 35 · 2025: 55 · 2024: 56 · 2023: 62 · 2022: 91 · 2021: 61 · 2020: 68 · 2019: 16
FWCI: 41.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: HHS | NIH | National Center for Advancing Translational SciencesHHS | NIH | National Center for Advancing Translational Sciences (NCATS) (TL1TR001880)
American Society of Clinical OncologyAmerican Society of Clinical Oncology (ASCO)
HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R21 CA198621, R01 CA198089, R01 CA166616, K08 CA187577)
Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (CI-99-18)
Biff Ruttenberg Foundation
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords: acute myeloid leukemia, FLT3 mutation, gilteritinib, FLT3 inhibitor resistance, clonal selection, clonal evolution, NRAS mutation, KRAS mutation, BCR-ABL fusion gene, tyrosine kinase inhibitor resistance, single-cell DNA sequencing
MeSH terms: Adult, Aged, Aged, 80 and over, Aniline Compounds, Female, Humans, Male, Middle Aged, Mutation, Pyrazines, Signal Transduction, Leukemia, Myeloid, Acute, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, fms-Like Tyrosine Kinase 3, Young Adult, Single-Cell Analysis, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks